NCT07324109

Brief Summary

This study tests whether a vibration-based feedback device (Suralis) can reduce phantom limb pain in people with lower-leg amputations over 3 weeks. Participants wear the device daily and report pain levels, walking ability, and quality of life - with no known risks, as it's a CE-certified medical device. If pain improves, the study team will help participants apply for insurance coverage to keep using the system long-term. The goal is to offer a simple, non-drug option that may help ease chronic pain and improve daily function for amputees. Participation is voluntary and can be stopped anytime without affecting medical care.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
3mo left

Started Apr 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress83%
Apr 2025Jul 2026

Study Start

First participant enrolled

April 1, 2025

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

December 23, 2025

Completed
15 days until next milestone

First Posted

Study publicly available on registry

January 7, 2026

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2026

Last Updated

January 7, 2026

Status Verified

December 1, 2025

Enrollment Period

1.3 years

First QC Date

December 23, 2025

Last Update Submit

December 23, 2025

Conditions

Keywords

Phantom limb painVibrotactile feedbackLower limb amputationSuralis systemPain management

Outcome Measures

Primary Outcomes (1)

  • Visual Analogue Scale (VAS)

    Scores range from 0 to 100 mm, where 0 mm = "no phantom pain" and 100 mm = "worst imaginable phantom pain"; higher scores indicate greater pain intensity.

    Baseline (t1), end of 3-week intervention (t3), and 3-week follow-up (t4) - assessed via daily VAS entries averaged per time point.

Secondary Outcomes (3)

  • German Pain Questionnaire DSF - subscales

    Baseline (t1), end of 3-week intervention (t3), and 3-week follow-up (t4) - completed in person at study center.

  • Timed Up-and-Go (TUG) test

    Baseline (t1), end of 3-week intervention (t3), and 3-week follow-up (t4) - performed once per visit at study center.

  • 6-Minute Walk Test (6MWT)

    Baseline (t1), end of 3-week intervention (t3), and 3-week follow-up (t4) - performed once per visit at study center; distance in meters recorded.

Study Arms (1)

Intervention with Suralis System

EXPERIMENTAL

All participants receive a 3-week intervention with the Suralis vibrotactile feedback system, which provides real-time pressure-based sensory feedback via a sensorized insole and thigh-mounted vibrating cuff, calibrated individually via smartphone app to support pain reduction and gait stability.

Device: Vibrotactile sensory feedback

Interventions

The Suralis system delivers real-time vibrotactile feedback via four pressure sensors embedded in a prosthetic insole, each mapped to a corresponding vibration motor on a thigh cuff. Participants wear the device during daily ambulation for 3 weeks. Vibration parameters (threshold, intensity, duration, spatial mapping) are individually calibrated via a smartphone app to match each user's sensory perception and gait pattern. The system operates autonomously, requires daily charging, and logs usage data via Bluetooth. No additional therapy or medication is administered alongside the device. The intervention aims to modulate cortical reorganization and reduce phantom limb pain while improving gait confidence and safety, particularly under non-visual conditions (e.g., stepping backward or sideways). The device is CE-marked (UDI: FBS 1 912012142) and classified as a Class IIa medical device under EU MDR 2017/746.

Intervention with Suralis System

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Unilateral major lower-limb amputation (transtibial or transfemoral)
  • Presence of persistent phantom limb pain, defined as daily pain intensity ≥ 3/10 on the Visual Analog Scale (VAS) during the baseline period
  • Regular daily use of a prosthetic limb (minimum 4 hours/day)
  • Adequate German language proficiency to understand and complete study questionnaires and follow study procedures
  • Ability to provide informed consent

You may not qualify if:

  • Unstable wound or skin condition at the residual limb
  • Inconsistent prosthetic use (less than daily or \< 4 hours/day)
  • Poorly fitting or non-functional prosthesis (as determined by study team)
  • Incapacity to provide informed consent (e.g., due to cognitive impairment or severe psychiatric illness)
  • Insufficient German language skills to comprehend study materials or complete assessments reliably

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

MEDIAN Rehab Center Wiesbaden Sonnenberg

Wiesbaden, Hesse, 65191, Germany

RECRUITING

Related Links

MeSH Terms

Conditions

Phantom LimbAgnosia

Condition Hierarchy (Ancestors)

Perceptual DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesPain, PostoperativePostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsSigns and SymptomsPain

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr. med. Johannes Schroeter

Study Record Dates

First Submitted

December 23, 2025

First Posted

January 7, 2026

Study Start

April 1, 2025

Primary Completion (Estimated)

July 31, 2026

Study Completion (Estimated)

July 31, 2026

Last Updated

January 7, 2026

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

Locations